Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01078636 · ClinicalTrials.gov registry record

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

A clinical trial of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Alzheimer's Disease Cooperative Study (ADCS).

Completed
Registry status
342
Enrollment target
20
Study locations

NCT01078636: Completed study of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Alzheimer's Disease Cooperative Study (ADCS).

NCT01078636 is a study of Mild Cognitive Impairment and Alzheimers Disease that has completed, run by Alzheimer's Disease Cooperative Study (ADCS). The registered enrollment target is 342 participants, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01078636, a study of Mild Cognitive Impairment and Alzheimers Disease, has completed, sponsored by Alzheimer's Disease Cooperative Study (ADCS).

COMPLETED
Registry status
342 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI-GO seeks to define and characterize the mildest symptomatic phase of AD, referred to in this study as early amnestic MCI (EMCI). This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.

Conditions Studied

Mild Cognitive Impairment Alzheimers Disease

Study Locations (20)

California

  • University of California, Irvine - Irvine
  • University of California, Irvine - BIC - Irvine
  • University of Southern California - Los Angeles
  • University of California, Los Angeles - Los Angeles
  • University of California, Davis - Martinez
  • Stanford University - Palo Alto
  • University of California, San Diego - San Diego
  • University of California, San Francisco - San Francisco

Florida

  • Mayo Clinic, Jacksonville - Jacksonville
  • Wien Center - Miami Beach
  • Premiere Research Institute - West Palm Beach

Arizona

  • Banner Alzheimer's Institute - Phoenix
  • Banner Sun Health Research Institute - Sun City

District of Columbia

  • Georgetown University - Washington D.C.
  • Howard University - Washington D.C.

Illinois

  • Northwestern University - Chicago
  • Rush University Medical Center - Chicago

Alabama

  • University of Alabama at Birmingham - Birmingham

Connecticut

  • Yale University School of Medicine - New Haven

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 342 participants
Start Date 2010-04
Est. Completion 2012-10
Alzheimer's Disease Cooperative Study (ADCS)

10 total trials

What the finished NCT01078636 record still lists

NCT01078636 is an observational study that tracks outcomes without assigning an intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, below the 1,269-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (73% lower).

The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.

NCT01078636 names 20 study sites across 8 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT01078636 about?

NCT01078636 is a clinical study titled "Alzheimer's Disease Neuroimaging Initiative Grand Opportunity". The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (A...

What is the current status of trial NCT01078636?

This trial is currently completed. The enrollment target is 342 participants. The study started on 2010-04. Estimated completion is 2012-10.

What conditions does trial NCT01078636 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimers Disease.

Who is sponsoring clinical trial NCT01078636?

This trial is sponsored by Alzheimer's Disease Cooperative Study (ADCS), which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01078636 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01078636's enrollment target sits among peer trials

342 28th of 205 higher than 178 of 205 other Mild Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05283850 · 342 participants · Phase 2

    Surviving PEA in Roanoke (SPEAR) Study

  • NCT05714085 · 342 participants · Phase 2

    Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

  • NCT06188702 · 342 participants · Phase 1

    S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

  • NCT06544941 · 342 participants · NA

    Improving Maternal Sleep and Mental Health

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01078636, the US trial registry maintained by the National Library of Medicine. NCT01078636 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.